drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous cellular therapy)
drug_description
Autologous CAR T-cell therapy engineered to target CD19 on B cells with a CD34 truncation tag for selection, metabolically programmed toward a Th1/Th17-like phenotype to enhance cytotoxicity, persistence, and fitness.
nci_thesaurus_concept_id
C202931
nci_thesaurus_preferred_term
CD19-CD34tagged Metabolically Programmed CAR T-cells
nci_thesaurus_definition
A preparation of a subset of T-lymphocytes, that are metabolically enhanced based on selection and purification on CD34 expression and primed to contain T-helper subset 1 and 17 (Th1/17 hybrid cells), that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, CD19-CD34tagged metabolically programmed CAR T-cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. These T-cells may show enhanced persistence and effector function as compared to other, non-metabolically enhanced, anti-CD19 CAR T-cells.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that recognizes CD19 on B cells. A CD34 truncation tag enables selection/purification of CAR+ cells, and metabolic programming biases the product toward a Th1/Th17 phenotype to enhance cytotoxicity, persistence, and fitness. Upon infusion, CAR engagement of CD19 activates the T cells to release cytokines and lyse CD19+ malignant B cells.
drug_name
CD19-CD34t metabolically programmed CAR T cells
nct_id_drug_ref
NCT05702853